OptiBiotix Health Regulatory News (OPTI)

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Appointment of Dr Gareth Barker as Non-Executive Director

OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the appointment of Dr Gareth Barker as a Non-Executive Director of the Company.

Dr Gareth Barker is Vice President of Human Nutrition and Health for DSM Nutritional Products Europe AG, the global science-based nutrition company, within Europe, Africa and the Middle East. Prior to this he has worked in a number of roles for DSM including Global Head of Marketing for DSM's Human Nutrition and Health Division and Sales Director in the Asia Pacific region, with responsibilities including launch strategies for Nutraceuticals. Gareth's career has given him extensive experience and understanding of global markets within the health and nutrition sector.

Before joining DSM, Gareth worked for Hoffmann-la-Roche who he joined after working in consultancy advising clients in the Food & Pharmaceutical industries. Gareth has an MBA from Manchester Business School, a PhD from Oxford University, and is proficient in French, Spanish, and German.

DSM is a global science-based company active in health, nutrition and materials with a strong market focus. It has a marketing/sales presence in over 60 countries and is focused on translating market needs into successful products which bring health benefits to its customers. It is the world's largest vitamin producer and hold leading positions in the ingredient markets for human and animal nutrition and health as well as personal care.

Stephen O'Hara, CEO of OptiBiotix, commented: "Gareth's experience and understanding of global markets in human health and nutrition brings valuable market insight to OptiBiotix. Gareth's expertise and guidance will help ensure the development of products which meet customer needs in global markets. This is consistent with our core strategy of developing products with a customer focus, supported by a strong scientific evidence base, to build a successful and sustainable business for our customers and shareholders. At OptiBiotix, we believe that better science equals better health and we strive to ensure this becomes a reality."

The following information is disclosed pursuant to Schedule 2(g) of the AIM Rules for Companies:

Dr Gareth Allan Barker, aged 48, has held the following directorships or partnerships in the past 5 years:

Dr Barker does not currently own any shares in the Company.

There is no further information to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

About DSM - www.dsm.com

DSM - Bright Science. Brighter Living.™

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 24,500 employees deliver annual net sales of around €10 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.